Navigation Links
Hadasit Bio-Holdings CEO Letter to Shareholders
Date:4/9/2013

d completing a merger with a public company. Despite a difficult year in regards to the Company's value, we believe that HBL has reached a trough and are now positioned to thrive both clinically and financially in 2013; thus bringing strong returns to the portfolio and its investors.

In the following I've outlined the Company's recent developments and our future plans, which we hope you will partake in as a potential shareholder.

Recent Developments:

Successful Clinical Trials

  • Following a Phase I clinical trial with THR-18, which was designed to show safety of Thrombotech's lead product for the treatment of stroke victims, the company was merged into a publicly traded company, D-Pharm, and is now conducting a Phase II clinical trial. The Phase I trial showed positive initial results of efficacy in treating additional conditions as well.
  • Enlivex completed a Phase I/II study on patients undergoing bone marrow transplants and was successful in showing a very significant reduction in Graft vs Host Disease (GVHD) severity.
  • BioMarCare has collected hundreds of samples from cancer patients for its development of cancer diagnostic kits, as part of a clinical trial.

New Strategic Partners and Additional Investments 

  • Micromedic Technologies Ltd. invested in our BioMarCare Technologies Ltd.
  • Sanofi and Recipharm invested 10M NIS in our portfolio company KAHR Medical Ltd.
  • Clal Biotechnology Industries and Pontifax provided ProtAb with additional funds to support its current activities and prepare for a broad clinical trial.
  • BioTime Inc. signed an agreement to provide Cell Cure with $3.5M of BioTime stock.

Grants and Financial Achievements

  • BioMarCare received a grant from the Israel-U.S. Binationa
    '/>"/>

SOURCE Hadasit Bio-Holdings Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
2. KAHR Medical, a Hadasit Bio-Holdings Portfolio Company, to Raise $2.6 Million
3. Hadasit Bio-Holdings Interviewed by Wall Street Reporter
4. Hadasit Bio-Holdings Ltd. Portfolio Companies - ProtAb Ltd. and KAHR Medical Ltd. to Receive NIS 10.7 Million (Over $2.8 Million USD) in Additional Government Grants
5. NeoStems CEO Letter to Shareholders
6. Genesis Biopharma Issues Letter To Shareholders
7. Bacterin Receives Letter From NYSE MKT LLC Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders
8. Elsevier to Participate in SCOAP3 With the Journals Physics Letters B and Nuclear Physics B
9. Ronald L. Chez Files Amended 13D and Letter to the Board
10. Mangrove Partners Sends Letter to Stockholders of Nabi Biopharmaceuticals
11. Amarantus BioSciences Issues CEO Letter to Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Array BioPharma Inc. (NASDAQ: ARRY ... agreement with Novartis Pharma AG to acquire worldwide rights ... 3 development.  This agreement is conditional on the closing of ... 22, 2014, which are expected to close in the ...
(Date:1/22/2015)... BOSTON , Jan. 22, 2015  Transwestern | RBJ today ... feet of office space for Shire a leading biopharmaceutical company, ... . Transwestern | RBJ,s Robert Richards , president, and ... the lease for the entire five-floor building at 95 Hayden ...
(Date:1/22/2015)... laboratory information management systems market is a rapidly growing ... due to factors such as rising pressure to comply ... and increasing government support for adoption of HCIT solutions ... the market focus on technological advancements to further the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 zFlo Motion ... pleased to announce an exciting product from a new partner. ... analysis solutions over the past 15 years, with offerings in ... recently, their 3D IMU system (inertial measurement unit), iSen, is ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 43D Motion Capture Just Got Easy 2
... of Americans Want President-Elect Obama to Deliver on Campaign ... - WASHINGTON, Jan. 14 The Coalition for the ... paper, Catalyst For Cures: Embryonic Stem Cell Research ... nation,s leading scientists on the promises and challenges of ...
... Jan. 14 With all the woes of the U.S. ... better opportunities. After all, China is expected to become ... As the world watches, China is becoming a driving force ... viable in this marketplace must learn to either thrive or ...
... ARAY ), a global leader in the field of ... quarter fiscal year 2009, ending,December 27, 2008, on Thursday, January ... A conference call to review the results will begin ... hosted by Euan S. Thomson, Ph.D., president and chief,executive officer, ...
Cached Biology Technology:Coalition for the Advancement of Medical Research Releases New White Paper, 'Catalyst for Cures: Embryonic Stem Cell Research' 2Coalition for the Advancement of Medical Research Releases New White Paper, 'Catalyst for Cures: Embryonic Stem Cell Research' 3Cracking the Code: Exclusive Conference to Reveal Secrets of Chinese Pharmaceutical Industry 2Accuray Incorporated to Report Second Quarter Fiscal Year 2009 Financial Results 2
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ... the "Global Wearable Technologies Market and Applications, ... Trends and Forecast 2014-2020" report to their ... smart devices that can be worn on the ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides ... and fingerprinting markets. Watermarking aims to control and ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2
... identified genes that may be important for preventing childhood ... of the blood that occurs primarily in young children. ... that arise during embryonic or fetal development. ... two key genes that appear essential in the prevention ...
... extinction around the globe, efforts to save the Grand ... chance for complete recovery, according to health experts from ... of the Blue Iguana Recovery Program. Coordinated by ... Iguana Recovery Programa consortium of local and international partnershas ...
... 16th, 2011 BGI (formerly known as Beijing ... world, and National Wolfberry Engineering Research Center of ... announced to initiate "Chinese Wolfberry Genome Project". This ... wolfberry production with high yields and good quality, ...
Cached Biology News:Research identifies genes vital to preventing childhood leukemia 2Grand Cayman blue iguana: Back from the brink of extinction 2BGI and National Wolfberry Engineering Research Center launch Chinese wolfberry genome project 2
... is obtained from non-demolished blood ... fasted donors. The donors are ... and are maintained on an ... Protein Concentration : 85 mg/ml ...
Alkaline Phosphatase (E. coli C75), 100 units. Removes 5'-phosphates from DNA. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Alkaline Phosphatases....
... cDNA Labeling Kit with CyScribe GFX ... generation and purification of Cy3- and ... for complete cDNA labeling and purification.Flexible ... for performing labeling reactions with either ...
... CyScribe Post-Labeling Kit with CyScribe ... the generation and purification of Cy3- ... together for complete cDNA labeling and ... used for performing labeling reactions with ...
Biology Products: